¼¼°èÀÇ ÇÏÀÌ¿£µå ¼¿·Î¹Í½º ½ÃÀå
High End Cellomics
»óǰÄÚµå : 1747777
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 212 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,020,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,062,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÇÏÀÌ¿£µå ¼¿·Î¹Í½º ¼¼°è ½ÃÀåÀº 2030³â±îÁö 70¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 46¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÇÏÀÌ¿£µå ¼¿·Î¹Í½º ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 7.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 70¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ±â±â´Â CAGR 6.2%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 38¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½Ã¾à ¹× ¼Ò¸ðǰ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 8.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 12¾ï ´Þ·¯·Î ÃßÁ¤¡¤¿¹Ãø, Áß±¹Àº CAGR 7.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÇÏÀÌ¿£µå ¼¿·Î¹Í½º ½ÃÀåÀº 2024³â¿¡ 12¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 11¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 7.1%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 6.5%¿Í 6.2%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 6.0%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ÇÏÀÌ¿£µå ¼¿·Î¹Í½º ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Á¤¹Ð Á¶»ç¿¡¼­ ÇÏÀÌ¿£µå ¼¿·Î¹Í½º°¡ ºü¸£°Ô ºÎ»óÇÏ´Â ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

ÇÏÀÌ¿£µå ¼¿·Î¹Í½º´Â ´ÜÀÏ ¼¼Æ÷ ºÐ¼®, »ý¼¼Æ÷ À̹Ì¡, °íÇÔ·® ½ºÅ©¸®´×¿¡ ÀÖ¾î Àü·Ê ¾ø´Â ´É·ÂÀ» Á¦°øÇÔÀ¸·Î½á ¹ÙÀÌ¿À¸ÞµðÄà ¿¬±¸ ¹ßÀü¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ºÐ¾ß·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß´Â ÷´Ü ¹ÙÀÌ¿À À̹Ì¡, ¸Ó½Å·¯´× ¾Ë°í¸®Áò, ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ±â¼úÀ» À¶ÇÕÇÏ¿© ¼¼Æ÷ÀÇ °Åµ¿À» Ãʹ̼¼ ÀÔÀÚ ¼öÁØ¿¡¼­ ÇØµ¶ÇÏ´Â ºÐ¾ßÀÔ´Ï´Ù. ÀÌ ºÐ¾ß¸¦ º¯È­½ÃŰ´Â ÇÙ½É Æ®·»µå´Â ±âÁ¸ÀÇ Áý´Ü ±â¹Ý ºÐ¼®¿¡¼­ ¼¼Æ÷ÀÇ ÀÌÁú¼ºÀ» Á¦°ÅÇÏ¿© º¸´Ù Á¤È®Çϰí ÀÓ»ó°ú °ü·ÃµÈ ÅëÂû·ÂÀ» Á¦°øÇÏ´Â ´ÜÀÏ ¼¼Æ÷ Á¢±Ù¹ýÀ¸·ÎÀÇ ÀüȯÀÔ´Ï´Ù. °í󸮷® Çö¹Ì°æ °Ë»ç¿Í ½Ç½Ã°£ AI Áö¿ø ºÐ¼®ÀÇ ÅëÇÕÀ¸·Î Á¤Àû ½º³À¼¦»Ó¸¸ ¾Æ´Ï¶ó ½Ã°£ °æ°ú¿¡ µû¸¥ µ¿Àû ¼¼Æ÷ À̺¥Æ®¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ°Ô µÇ¾î ¿¬±¸ÀÚµéÀº ½ÅÈ£ Àü´Þ ij½ºÄÉÀ̵å, ¼¼Æ÷ÁÖ±â Àüȯ, ¼¼Æ÷ »ç¸ê °úÁ¤À» ³ôÀº Ãæ½Çµµ·Î ÃßÀûÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

¸ÖƼ¿À¹Í½º ±â¼úÀÇ ±Þ°ÝÇÑ ¹ßÀüÀº ¼¿·Î¹Í½ºÀÇ ¹üÀ§¸¦ ´õ¿í È®Àå½ÃÄ×½À´Ï´Ù. °³º° ¼¼Æ÷¿¡¼­ À¯Àüü, Àü»çü, ÇÁ·ÎÅ׿È, ´ë»çü ÇÁ·ÎÆÄÀÏÀ» »óÈ£ ¿¬°ü½Ãų ¼ö ÀÖ´Â ´É·ÂÀº ÀÌ ºÐ¾ß¸¦ ´Ü¼øÇÑ ½Ã°¢È­ÀÇ ¿µ¿ªÀ» ³Ñ¾î¼±´Ù. ÇÏÀÌ¿£µå ¼¿·Î¹Í½º Ç÷§ÆûÀº ÀÌÁ¦ Á¾¾ç ¹Ì¼¼È¯°æ, ¸é¿ª¼¼Æ÷ ±â´É, Áٱ⼼Æ÷ ºÐÈ­¸¦ ´ÜÀÏ ¼¼Æ÷ ÇØ»óµµ·Î ÀÌÇØÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. ±× °á°ú, Á¦¾à»çµéÀº ƯÈ÷ Á¾¾çÇÐ, ¸é¿ªÄ¡·áÁ¦, ½Å°æÅðÇ༺ Ä¡·áÁ¦ °³¹ß¿¡¼­ °íÇÔ·® Ç¥ÇöÇü ½ºÅ©¸®´×À» À§ÇÑ ¼¿·Î¹Í½º Åø¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. Ä¡·áÁ¦ ¹ß±¼, µ¶¼ºÇÐ ÇÁ·ÎÆÄÀϸµ, ¼¼Æ÷ ±â¹Ý ºÐ¼® µî ±× À¯¿ë¼ºÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, ¼¿·Î¹Í½º´Â Â÷¼¼´ë Á¤¹ÐÀÇ·áÀÇ Áß¿äÇÑ ÃàÀ¸·Î °­È­µÇ°í ÀÖ½À´Ï´Ù.

À̹Ì¡, AI, À¯Ã¼°øÇÐÀÇ Çõ½ÅÀº ¾î¶»°Ô ¼¿·Î¹Í½º ŸŶÀ» À籸¼ºÇϰí Àִ°¡?

ÇÏÀÌ¿£µå ¼¿·Î¹Í½º ½ÃÀåÀÇ º¯È­ÀÇ Á߽ɿ¡´Â ±â¼úÀÇ ¼ö·ÅÀÌ ÀÖ½À´Ï´Ù. ÀÚ±Ø ¹ß±¤ °¨¼è¹ý(STED)°ú ±¸Á¶È­ Á¶¸í Çö¹Ì°æ(SIM) µî Çü±¤ Çö¹Ì°æ°ú ÃÊÇØ»óµµ Çö¹Ì°æÀÇ Çõ½ÅÀº ¼¼Æ÷ ³» ¿¬±¸¿¡ ÇÊ¿äÇÑ ÇØ»óµµ¿Í ´ëºñ¸¦ Å©°Ô Çâ»ó½ÃÄ×½À´Ï´Ù. »ý¼¼Æ÷ À̹Ì¡ ±â´É°ú °áÇÕÇÏ¿© ¿¬±¸ÀÚµéÀº ÃÖ¼ÒÇÑÀÇ ±¤µ¶¼ºÀ¸·Î ¼¼Æ÷ ³» »óÈ£ ÀÛ¿ë°ú Ç¥ÇöÇü º¯È­¸¦ ½Ã°£ °æ°ú¿¡ µû¶ó °üÂûÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ±¤ÇÐ ºÎǰÀÇ ¼ÒÇüÈ­¿Í ÀÚµ¿ Ç÷¹ÀÌÆ® Çڵ鸵 ½Ã½ºÅÛÀÇ ÅëÇÕÀ¸·Î ÇÑ ¹øÀÇ ½ÇÇè¿¡¼­ ¼ö¹é, ¼öõ °³ÀÇ À£¿¡ °ÉÃÄ È®Àå °¡´ÉÇÑ À̹Ì¡ ¿öÅ©Ç÷ο츦 ±¸ÇöÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

ÀΰøÁö´ÉÀº ÇÏÀÌ¿£µå ¼¿·Î¹Í½º¿¡¼­ ¾ø¾î¼­´Â ¾È µÉ Áõ°­ ÀÎÀÚ·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀº ÀÚµ¿È­µÈ À̹ÌÁö ¼¼ºÐÈ­, Ư¡ ÃßÃâ, ¿¹ÃøÀû Ç¥ÇöÇü °áÁ¤¿¡ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¹æ´ëÇÑ ¼¼Æ÷ À̹ÌÁö ¶óÀ̺귯¸®·Î ÈÆ·ÃµÈ µö·¯´× Ç÷§ÆûÀº ÀÌÁ¦ ¹Ì¹¦ÇÑ ÇüÅÂÇÐÀû º¯È­¸¦ ½Ç½Ã°£À¸·Î ºÐ·ùÇÒ ¼ö ÀÖ¾î º¸´Ù Á¤È®ÇÑ ¾à¹° È¿´É Å×½ºÆ®¿¡ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AI¸¦ ÅëÇÑ ÀÌ»ó ¡ÈÄ °¨Áö ¹× ±ËÀû ÃßÀûÀº ¼¿·Î¹Í½º¸¦ Á¤Àû ºÐ¼® µµ±¸¿¡¼­ µ¿Àû ÀÇ»ç°áÁ¤ ½Ã½ºÅÛÀ¸·Î ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ½Ã½ºÅÛÀÇ Å¾Àç´Â ¸¶ÀÌÅ©·Î ½ºÄÉÀÏ¿¡¼­ Á¤È®ÇÑ ¼¼Æ÷ ¼±º°, ȯ°æ Á¦¾î, ½Ã¾à Àü´ÞÀ» ¿ëÀÌÇÏ°Ô ÇÔÀ¸·Î½á ¼¿·Î¹Í½º Ç÷§ÆûÀÇ ºÐ¼® ´É·ÂÀ» °­È­ÇÕ´Ï´Ù.

ÇÏÀÌ¿£µå ¼¿·Î¹Í½º´Â ¾î¶² ¿ëµµ·Î Ȱ¿ëµÇ°í Àִ°¡?

ÇÏÀÌ¿£µå ¼¿·Î¹Í½ºÀÇ ÀÀ¿ë ºÐ¾ß´Â ƯÈ÷ ½Å¾à°³¹ß, µ¶¼ºÇÐ, ¸é¿ªÇÐ, Àç»ýÀÇÇÐ ºÐ¾ß¿¡¼­ ºü¸£°Ô ´Ù¾çÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀǾàǰ ¿¬±¸ °³¹ß¿¡¼­ ¼¿·Î¹Í½º´Â ¹ÙÀÌ¿À¸¶Ä¿¿¡¸¸ ÀÇÁ¸ÇÏÁö ¾Ê°í ¼¼Æ÷ ¹× ÇÏÀ§ ¼¼Æ÷ ¼öÁØ¿¡¼­ ¾à¹° ¹ÝÀÀÀ» Æò°¡ÇÒ ¼ö Àֱ⠶§¹®¿¡ È­ÇÕ¹° ½ºÅ©¸®´×¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ¾à¹° °³¹ß ÆÄÀÌÇÁ¶óÀÎÀÇ Ãʱ⠴ܰ迡¼­ Ç¥Àû ¿Ü È¿°ú¸¦ È®ÀÎÇϰí Åõ¿© ¹æ¹ýÀ» ÃÖÀûÈ­ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ¾Ï ¿¬±¸´Â ¼¿·Î¹Í½º°¡ ÀÌÁ¾ Á¾¾ç »ùÇÃÇÁ·ÎÆÄÀϸµ, ¸é¿ª¼¼Æ÷ ħÀ± Æò°¡, Ä¡·á ÀúÇ×¼º ÆÐÅÏ ¿¹Ãø µî °úÇÐÀÚµéÀÇ ¹æ¹ýÀ» º¯È­½Ã۰í ÀÖ´Â ÁÖ¿ä ºÐ¾ß Áß ÇϳªÀÔ´Ï´Ù.

¸é¿ªÇп¡¼­ ¼¿·Î¹Í½º´Â ±âÁ¸ ¹æ¹ýÀ¸·Î´Â ºÒ°¡´ÉÇß´ø T¼¼Æ÷, B¼¼Æ÷, Ç׿øÁ¦½Ã¼¼Æ÷ÀÇ ±â´ÉÀû ÇÁ·ÎÆÄÀϸµÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ´Â ¹é½Å °³¹ßÀ̳ª ¸é¿ªÁ¾¾çÇп¡¼­ ¹Ì¼¼Á¶Á¤µÈ ¸é¿ª¼¼Æ÷ÀÇ ¸ð´ÏÅ͸µÀÌ ¼³°è ¹× À¯È¿¼º Æò°¡ÀÇ ÁöħÀÌ µÉ ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ Å« Àǹ̰¡ ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î Áٱ⼼Æ÷ »ý¹°Çеµ ºÐÈ­ °æ·Î¿Í °èÅë ÃßÀû, ÈļºÀ¯ÀüÇÐÀû º¯È­¸¦ ½Ã°£ °æ°ú¿¡ µû¶ó ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ°Ô µÇ¸é¼­ °í±Þ ¼¿·Î¹Í½ºÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. ÀÓ»ó ¿¬±¸¼Ò¿Í CROµµ ȯÀÚ °èÃþÈ­ ¹× ¹ÙÀÌ¿À¸¶Ä¿ °ËÁõÀ» À§ÇØ ¼¿·Î¹Í½º ÅøÀ» µµÀÔÇϰí ÀÖÀ¸¸ç, ¼¼Æ÷ Áý´ÜÀ» ´ë±Ô¸ð·Î ºÐ¼®ÇÒ ¼ö ÀÖ´Â ´É·ÂÀº ¸ÂÃã Ä¡·á °èȹ°ú Áúº´ ÁøÇà ¸ð´ÏÅ͸µ¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌó·³ ÀüÀÓ»ó ¹× Áß°³ ȯ°æ¿¡¼­ÀÇ È°¿ëÀÌ È®´ëµÇ°í ÀÖ´Â °ÍÀº Çö´ë »ý¸í°úÇп¡¼­ ÇÏÀÌ¿£µå ¼¿·Î¹Í½ºÀÇ È°¿ë ¹üÀ§°¡ ³Ð¾îÁö°í ÀÖ´Ù´Â °ÍÀ» ÀÔÁõÇÕ´Ï´Ù.

ÇÏÀÌ¿£µå ¼¿·Î¹Í½º ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµË´Ï´Ù.

¼ºÀåÀÇ ¿øµ¿·ÂÀº ÁÖ·Î Á¦¾à ¹× »ý¸í°øÇÐ »ê¾÷¿¡¼­ °íÇÔ·® ºÐ¼® Ç÷§ÆûÀÇ °íµµÈ­ ¹× ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÃËÁø¿äÀÎ Áß Áß¿äÇÑ °ÍÀº ¿¹Ãø µ¶¼ºÇÐ ¹× Ç¥ÇöÇü ½ºÅ©¸®´× ½Ã½ºÅÛ¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¼¿·Î¹Í½º´Â ±âÁ¸ ¹æ½Ä¿¡ ºñÇØ ¿ì¼öÇÑ Ã³¸®·®°ú Á¤È®µµ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ¸é¿ªÄ¡·á ¹× ¼¼Æ÷Ä¡·áÁ¦ ÆÄÀÌÇÁ¶óÀÎÀÇ È®´ë·Î ÀÎÇØ ¸é¿ª¹ÝÀÀÀ» ´ÜÀÏ ¼¼Æ÷ ¼öÁØ¿¡¼­ ÀÌÇØÇϱâ À§ÇÑ °íÇØ»óµµÀÇ ¿ªµ¿ÀûÀÎ À̹Ì¡ µµ±¸°¡ ÇÊ¿äÇÕ´Ï´Ù. ¶ÇÇÑ, ¸ÖƼÇ÷º½º ºÐ¼®°ú ÇÏÀ̽º·çDz ½ºÅ©¸®´× Ä·ÆäÀÎÀÇ È®»êÀ¸·Î À̹Ì¡, µ¥ÀÌÅÍ ºÐ¼®, ÀÚµ¿È­¸¦ °áÇÕÇÑ ÅëÇÕ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Çмú¿¬±¸¼¾ÅÍ¿Í Áß°³¿¬±¸¼¾Å͵µ º¹ÀâÇÑ Áúº´ ¸ÞÄ¿´ÏÁòÀ» ±Ô¸íÇϰí Ä¡·á Ç¥ÀûÀ» °ËÁõÇÏ´Â ´É·ÂÀ» Çâ»ó½Ã۱â À§ÇØ ÇÏÀÌ¿£µå ¼¿·Î¹Í½º Ç÷§Æû¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ȯÀÚ À¯·¡ ¿À°¡³ëÀ̵å¿Í 3D ¼¼Æ÷ ¹è¾ç ½Ã½ºÅÛÀÇ Á߿伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ºñ´ÜÀÏ ºÐÀÚÃþ ±¸Á¶ÀÇ À̹Ì¡ ¹× ºÐ¼®ÀÌ °¡´ÉÇÑ Ç÷§Æû¿¡ ´ëÇÑ ½ÃÀåÀÇ °ü½ÉÀÌ ´õ¿í ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ý¸í°úÇÐ ¿¬±¸, ƯÈ÷ Á¾¾çÇÐ, ½Å°æ°úÇÐ, Èñ±ÍÁúȯ µîÀÇ ºÐ¾ß¿¡¼­ Á¤ºÎ ¹× ¹Î°£ÀÇ ÀçÁ¤Àû Áö¿øÀÌ Ã·´Ü ¼¿·Î¹Í½º ½Ã½ºÅÛÀÇ º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ±¤ÇÐ Çϵå¿þ¾î, °è»ê »ý¹°ÇÐ, ºÐ¼®±â ¼ÒÇüÈ­ÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î °í±Þ ¼¿·Î¹Í½º µµ±¸´Â º¸´Ù Á¢±Ù¼ºÀÌ ³ô°í, È®À强ÀÌ ¶Ù¾î³ª¸ç, º¸´Ù ±¤¹üÀ§ÇÑ °úÇÐÀû ޱ¸¿¡ Àû¿ëµÉ ¼ö ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(Àåºñ, ½Ã¾à ¹× ¼Ò¸ðǰ, ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º), ¿ëµµ(Drug Discovery, ¾Ï ¿¬±¸, ½Å°æ°úÇÐ, Áٱ⼼Æ÷ ¿¬±¸£¦Àç»ýÀÇ·á, ¸ÂÃãÇü ÀÇ·á, ±âŸ ¿ëµµ), ±â¼ú(Çö¹Ì°æ, À¯¼¼Æ÷ºÐ¼®±â, ½Ì±Û ¼¿ À¯ÀüüÇÐ, Áú·®ºÐ¼®, Â÷¼¼´ë ½ÃÄý½Ì, ±âŸ ±â¼ú), ÃÖÁ¾ ¿ëµµ(Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, º´¿ø ¹× Áø´Ü½ÇÇè½Ç, °è¾à ¿¬±¸±â°ü, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 34°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»±¹, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÍ¿ø°¡ Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <>& Áß±¹ <>& ¸ß½ÃÄÚ <>& ij³ª´Ù <>&EU <>& ÀϺ» <>& Àεµ <>& ±âŸ 176°³±¹

¾÷°è¸¦ ¼±µµÇÏ´Â ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·®°æÁ¦ »óȲ¿¡¼­ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤À» Àû¿ëÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global High End Cellomics Market to Reach US$7.0 Billion by 2030

The global market for High End Cellomics estimated at US$4.6 Billion in the year 2024, is expected to reach US$7.0 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$3.8 Billion by the end of the analysis period. Growth in the Reagents & Consumables segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 7.1% CAGR

The High End Cellomics market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.5% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.

Global High-End Cellomics Market - Key Trends & Drivers Summarized

What Is Driving the Rapid Emergence of High-End Cellomics in Precision Research?

High-end cellomics is emerging as a pivotal discipline in the evolving landscape of biomedical research, offering unprecedented capabilities in single-cell analysis, live-cell imaging, and high-content screening. This field represents the fusion of advanced bioimaging, machine learning algorithms, and microfluidic technologies to decode cellular behavior at an ultra-granular level. A core trend transforming the sector is the shift from traditional population-based assays to single-cell approaches that eliminate cellular heterogeneity and yield more precise, clinically relevant insights. The integration of high-throughput microscopy with real-time AI-enabled analysis has made it possible to capture not just static snapshots but dynamic cellular events over time, allowing researchers to track signaling cascades, cell cycle transitions, and apoptotic processes with high fidelity.

A parallel surge in multi-omics technologies has further enhanced the scope of cellomics. The capacity to correlate genomic, transcriptomic, proteomic, and metabolomic profiles from individual cells has propelled the field beyond mere visualization. High-end cellomics platforms are now essential for understanding tumor microenvironments, immune cell function, and stem cell differentiation at single-cell resolution. As a result, pharmaceutical companies are investing heavily in cellomics tools for high-content phenotypic screening, especially in oncology, immunotherapy, and neurodegenerative drug development. The expanding utility across therapeutic discovery, toxicological profiling, and cell-based assays is reinforcing cellomics as a critical pillar in the next generation of precision medicine.

How Are Innovations in Imaging, AI, and Fluidics Reshaping the Cellomics Toolkit?

Technological convergence lies at the heart of the high-end cellomics market transformation. Innovations in fluorescence and super-resolution microscopy, such as stimulated emission depletion (STED) and structured illumination microscopy (SIM), have substantially improved the resolution and contrast needed for subcellular studies. Coupled with live-cell imaging capabilities, researchers can now observe intracellular interactions and phenotypic changes over time with minimal phototoxicity. This is further supported by the miniaturization of optical components and the integration of automated plate handling systems, enabling scalable imaging workflows across hundreds or thousands of wells in a single experiment.

Artificial intelligence has emerged as an indispensable force multiplier in high-end cellomics. Machine learning algorithms are increasingly used for automated image segmentation, feature extraction, and predictive phenotyping. Deep learning platforms trained on vast libraries of cellular images now allow real-time classification of subtle morphological changes, aiding in more precise drug efficacy testing. Moreover, AI-driven anomaly detection and trajectory tracking have elevated cellomics from a static analysis tool to a dynamic decision-making system. The inclusion of microfluidic systems has also bolstered the analytical capabilities of cellomics platforms by facilitating precise cell sorting, environmental control, and reagent delivery at the microscale, which is particularly vital for longitudinal studies on rare cell populations.

Where Is High-End Cellomics Gaining Ground Across Applications?

The applications of high-end cellomics are rapidly diversifying, particularly within the realms of drug discovery, toxicology, immunology, and regenerative medicine. In pharmaceutical R&D, cellomics plays a key role in compound screening, allowing researchers to assess drug responses at the cellular and subcellular levels without relying on biomarkers alone. This is critical for identifying off-target effects and optimizing dosage regimes early in the drug development pipeline. Cancer research stands out as a dominant domain where cellomics is transforming how scientists profile heterogeneous tumor samples, evaluate immune cell infiltration, and predict therapeutic resistance patterns.

In immunology, cellomics enables functional profiling of T cells, B cells, and antigen-presenting cells in ways not possible through traditional methods. This has profound implications for vaccine development and immune-oncology, where fine-tuned immune cell monitoring can guide both design and efficacy evaluation. Similarly, stem cell biology is benefiting from high-end cellomics by enabling researchers to monitor differentiation pathways, lineage tracing, and epigenetic shifts over time. Clinical laboratories and CROs are also deploying cellomics tools for patient stratification and biomarker validation, where the ability to analyze cell populations at scale supports personalized treatment planning and disease progression monitoring. This growing use across preclinical and translational settings underscores the broadening reach of high-end cellomics in modern biosciences.

The Growth in the High-End Cellomics Market Is Driven by Several Factors…

It is primarily the increasing sophistication and demand for high-content analysis platforms in pharmaceutical and biotechnology industries that is fueling growth. Key among these drivers is the rising need for predictive toxicology and phenotypic screening systems, where cellomics offers superior throughput and accuracy compared to conventional methods. The expansion of immunotherapy and cell therapy pipelines has also necessitated high-resolution, dynamic imaging tools for understanding immune responses at the single-cell level. Furthermore, the proliferation of multiplexed assays and high-throughput screening campaigns is driving demand for integrated solutions that combine imaging, data analytics, and automation.

Academic and translational research centers are also investing in high-end cellomics platforms to enhance their ability to dissect complex disease mechanisms and validate therapeutic targets. The growing importance of patient-derived organoids and 3D cell culture systems has further bolstered market interest in platforms capable of imaging and analyzing non-monolayer structures. Additionally, government and private funding in life sciences research, particularly in areas like oncology, neuroscience, and rare diseases, is supporting the widespread adoption of advanced cellomics systems. Finally, the continuous advancements in optical hardware, computational biology, and assay miniaturization are making high-end cellomics tools more accessible, scalable, and applicable across a wider range of scientific inquiries.

SCOPE OF STUDY:

The report analyzes the High End Cellomics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Instruments, Reagents & Consumables, Software & Services); Application (Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine, Other Applications); Technology (Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing, Other Technologies); End-Use (Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â